Updated 2/23/26
While patients may never interact with their products directly, healthcare facilities around the world rely on STERIS every day. From sterilization systems to surgical equipment and infection prevention services, this is a business built around keeping medical environments safe, clean, and compliant.
Headquartered in Ireland but operating globally, STERIS has built a reputation for reliability and precision. It’s not a company chasing headlines—it’s quietly becoming an essential part of healthcare infrastructure. And for dividend-focused investors, that kind of consistency can be gold.
Recent Events
STERIS has maintained its steady operational cadence heading into early 2026. The company continues to benefit from durable demand across its healthcare, sterilization, and life sciences segments, with total revenue now running at approximately $5.83 billion on a trailing basis. Net income has reached $708.5 million, translating to earnings per share of $7.17—a figure that underscores the company’s ability to convert top-line growth into real bottom-line results.
Behind the scenes, management has continued its disciplined approach to capital deployment, balancing organic investment with selective bolt-on activity. The focus remains on deepening market position rather than pursuing transformational deals that could disrupt the financial stability the company has worked hard to establish.
Most importantly for income investors, STERIS raised its quarterly dividend to $0.63 per share in September 2025, a meaningful step up from the $0.57 quarterly rate that had been in place since September 2024. That increase keeps the company’s long dividend growth streak very much alive and reinforces management’s confidence in the underlying cash generation of the business.
Key Dividend Metrics
💰 Dividend Yield: 0.96%
📆 Dividend Growth Streak: 14+ years
📤 Five-Year Dividend Growth Rate: Approximately 9% annually
🛡️ Payout Ratio: 33.47%
🔁 Distribution Frequency: Quarterly
📅 Most Recent Payment: $0.63 per share (February 17, 2026)
🔎 Annual Dividend: $2.46 per share
Dividend Overview
STERIS offers a dividend that’s modest on the surface, but it’s the story behind the numbers that matters. A yield just under 1% may not raise eyebrows at first glance, but the company has a long and unbroken history of raising that payout. The most recent increase, which lifted the quarterly payment from $0.57 to $0.63 per share beginning with the September 2025 distribution, represents a roughly 10.5% bump—continuing a pattern of increases that has now stretched across more than a decade.
This is a business that pays its dividend out of real profits and actual cash flow. The current payout ratio sits at just 33.47%, which is even more conservative than the prior year’s level, leaving substantial room for continued increases. Management is not sacrificing reinvestment in the business to keep shareholders happy—they are managing both priorities with discipline.
For income investors with a long-term view, this is the kind of dividend you can count on to quietly grow in the background year after year. The absolute yield will always look modest against the starting price, but investors who have held STERIS for five or ten years have seen their yield-on-cost grow in a way that more than justifies the patience.
Dividend Growth and Safety
STERIS hasn’t just been consistent—it has been aggressive with dividend increases relative to what you might expect from a healthcare infrastructure company. The five-year average growth rate hovers around 9% annually, and the most recent increase of approximately 10.5% is right in line with that historical pace, suggesting no sign of deceleration.
The dividend is backed by strong free cash flow, which came in at $870.7 million over the trailing twelve months. With an annual dividend obligation that represents only a small fraction of that figure, the coverage is wide. Operating cash flow of $1.27 billion provides an even broader cushion, giving management flexibility to continue raising the payout while still funding capital expenditures and any strategic acquisitions.
The balance sheet remains in solid shape. With a price-to-book ratio of 3.39 and book value per share of $72.93, the equity base is substantial. Return on equity of 10.47% and return on assets of 6.61% reflect disciplined capital management rather than a business relying on financial engineering to inflate its numbers. The profit margin of 12.14% demonstrates that STERIS is consistently converting revenue into earnings without sacrificing the operational integrity that makes this business so predictable. Short interest of just 1.56 million shares is a low figure relative to the float, suggesting the institutional community is not positioning aggressively against this name.
The dividend is safe, and it is growing. That combination remains the standard dividend investors should be seeking, and STERIS continues to deliver it.
Analyst Ratings
While a formal set of updated analyst ratings is not currently available, the financial profile STERIS presents makes it straightforward to assess where the consensus likely sits. At $247.11 and a trailing P/E of 34.46, the stock is trading at a modest discount to the upper end of its 52-week range of $269.44, which suggests the market is pricing in stable but not accelerating growth. Prior analyst price targets from firms such as JMP Securities, Stephens & Co., and Piper Sandler had clustered in the $250 to $265 range, and given that earnings per share of $7.17 and free cash flow of $870.7 million continue to support those estimates, there is little fundamental reason to expect meaningful target reductions.
The broader analyst community has historically viewed STERIS as a well-positioned name in the medical technology space, with its consistent cash generation and durable recurring revenue streams making it a reliable hold even in uncertain macro environments. Morgan Stanley’s prior “Equalweight” stance, rooted in valuation concerns at higher price levels, becomes a less compelling argument at $247 given that the earnings base has continued to grow. At current levels, the stock trades roughly in line with its fundamental value, which is likely to keep the consensus somewhere between “Hold” and “Overweight” until a clearer near-term earnings catalyst emerges.
For dividend growth investors, the analyst framing is largely secondary to the underlying cash flow picture, which remains strong and supports the continued dividend growth that makes this name attractive in the first place.
Earning Report Summary
Based on the trailing twelve-month financials available through February 2026, STERIS is running at approximately $5.83 billion in total revenue with net income of $708.5 million and diluted EPS of $7.17. Operating cash flow of $1.27 billion and free cash flow of $870.7 million represent the strongest cash generation metrics the company has posted in recent years, reflecting both volume growth and continued operational efficiency improvements across its business segments.
Healthcare Segment
The Healthcare segment remains STERIS’s largest and most consistent revenue driver. Consumables and service revenues have continued to lead growth within the segment, benefiting from the high-recurrence nature of sterilization and infection prevention workflows inside hospital systems. Capital equipment demand has remained somewhat more variable, as it tends to be in healthcare infrastructure businesses, but the recurring service and consumable mix provides a durable earnings floor that insulates margins from short-term equipment cycle softness.
Applied Sterilization Technologies (AST)
The AST segment continues to be a standout performer within the STERIS portfolio. Contract sterilization demand has remained resilient, driven by the steady output of medical device manufacturers who rely on STERIS’s third-party sterilization capacity. This segment benefits from long-term customer contracts and relatively limited competition at scale, which together support both pricing power and margin stability. Operating income in this segment has tracked revenue growth closely, with incremental margins that reflect the capital-efficient nature of the service model.
Life Sciences
Life Sciences remains the smallest of the three major segments and has faced some headwinds tied to capital equipment order timing and the residual effects of prior divestitures. Pricing improvements and a favorable product mix have helped offset some of the volume pressure, and operating income in the segment has held up better than the top-line movement might suggest. Management’s focus on higher-margin consumable and service revenue within life sciences is helping to stabilize the profitability profile of the segment over time.
Cash Flow and Guidance
Cash flow generation has been the defining financial story at STERIS through the current fiscal year. Operating cash flow of $1.27 billion and free cash flow approaching $871 million represent a meaningful improvement over prior periods and give management significant flexibility in capital allocation. The dividend increase to $0.63 per quarter reflects management’s confidence that this cash generation is sustainable. With a payout ratio of just 33.47%, there remains ample room for continued dividend growth alongside ongoing capital investment in the business.
Financial Health and Stability
STERIS continues to present a financial profile built on stability rather than leverage or financial engineering. Return on equity of 10.47% and return on assets of 6.61% reflect consistent, disciplined execution across the business. These are not headline-grabbing numbers, but they represent a company that is reliably compounding shareholder value without taking on undue risk.
Cash generation is the centerpiece of the financial story. Operating cash flow of $1.27 billion gives the company more than enough capacity to fund capital expenditures, grow the dividend, and pursue strategic opportunities as they arise. The profit margin of 12.14% demonstrates that STERIS has maintained healthy conversion from revenue to net income even as the business has scaled.
Book value per share of $72.93 and a price-to-book ratio of 3.39 reflect the premium the market assigns to STERIS’s durable competitive position. The market cap of approximately $24.3 billion is well supported by the underlying cash flow dynamics of the business, and a beta of 1.04 suggests the stock behaves largely in line with the broader market rather than exhibiting the elevated volatility that would concern a long-term income investor.
Valuation and Stock Performance
At its current price of $247.11, STERIS trades at a trailing P/E of 34.46, which is on the higher side in absolute terms but consistent with the premium the market has historically assigned to high-quality healthcare infrastructure businesses. The price-to-book ratio of 3.39 reflects the value of the company’s durable recurring revenue streams and strong cash generation, both of which justify a meaningful premium to tangible book.
The 52-week range of $204.90 to $269.44 places the current price at roughly the midpoint, suggesting the stock has pulled back meaningfully from its highs without approaching the lower end of its recent range. For long-term investors, that positioning is arguably constructive—it reflects some of the valuation froth having been removed while the fundamental business continues to perform. A market cap of $24.25 billion against free cash flow of $870.7 million implies a price-to-free-cash-flow multiple of approximately 27.9x, which is elevated but not unreasonable for a business of this quality and consistency.
The stock has not been a momentum name over the trailing twelve months, but STERIS has rarely needed to be. The long-term compounding story here is driven by earnings growth, dividend increases, and the steady expansion of the company’s essential role in global healthcare infrastructure. Investors who have held this name through prior periods of valuation compression have been rewarded with continued dividend growth and eventual share price appreciation as fundamentals caught up to sentiment.
Risks and Considerations
Every company has risks, and STERIS is no exception. The most significant structural risk remains the regulatory environment. As a provider of sterilization and infection prevention equipment and services, STERIS must navigate complex and sometimes shifting regulations across multiple jurisdictions, including evolving standards around sterilization agents such as ethylene oxide. Any tightening of those standards could require meaningful capital investment or create operational disruptions in affected facilities.
Currency risk is also a real consideration given the company’s global footprint. A strengthening U.S. dollar relative to key operating currencies can compress reported revenues and earnings even when the underlying business is performing well. Management has been transparent about this dynamic in prior guidance updates, but it remains a variable that income investors should monitor.
From a dividend perspective, the most prominent limitation remains the low starting yield. At 0.96%, STERIS is not a name for investors seeking meaningful current income. The value proposition is built around dividend growth over time, which requires patience and a longer holding horizon than many income-focused investors are accustomed to.
Valuation at current levels also warrants attention. A P/E of 34.46 leaves limited margin for error. Any disappointment in earnings, whether driven by capital equipment softness, currency headwinds, or segment-level disruption, could result in meaningful share price pressure even if the long-term fundamentals remain intact. That is the trade-off investors accept when buying quality at a premium.
Final Thoughts
STERIS isn’t the kind of company that makes headlines, but for dividend investors, that’s not a bad thing. What it offers is consistency, safety, and a long runway for continued growth. It operates in a space where demand isn’t going away, and it has demonstrated quarter after quarter that it can deliver steady results across different market environments.
The dividend increase to $0.63 per quarter—representing an annual rate of $2.46 per share—is the latest proof point in a more than decade-long streak of consistent payout growth. With a payout ratio of just 33.47% and free cash flow of $870.7 million supporting the obligation many times over, there is no credible reason to question the safety or the trajectory of that dividend.
At $247.11, the stock is not cheap, but it rarely is. For investors focused on building a long-term, income-generating portfolio anchored by high-quality businesses, STERIS remains exactly the kind of quiet achiever that deserves a close look.